Drug Trial Radar · NCT07024693
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Design Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
Conditions
- Fuchs Endothelial Corneal Dystrophy
- Fuchs
Interventions
DT-168Drug
Active
Primary outcomes
What the sponsor says the trial is designed to measure.
- FECD Biomarkers: Splicing PanelTime frame: Perioperative
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
DTX-168-201 Study Site
Indianapolis, Indiana · Recruiting
DTX-168-201 Study Site
Grand Rapids, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.